CA2451674A1 - Composition d'un modificateur de reponse biologique et utilisations de celle-ci - Google Patents

Composition d'un modificateur de reponse biologique et utilisations de celle-ci Download PDF

Info

Publication number
CA2451674A1
CA2451674A1 CA002451674A CA2451674A CA2451674A1 CA 2451674 A1 CA2451674 A1 CA 2451674A1 CA 002451674 A CA002451674 A CA 002451674A CA 2451674 A CA2451674 A CA 2451674A CA 2451674 A1 CA2451674 A1 CA 2451674A1
Authority
CA
Canada
Prior art keywords
composition
brm
tumor
carcinoma
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002451674A
Other languages
English (en)
Inventor
Aiping H. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptose Bioscience Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002451674A priority Critical patent/CA2451674A1/fr
Priority claimed from PCT/CA2002/000932 external-priority patent/WO2002102363A1/fr
Publication of CA2451674A1 publication Critical patent/CA2451674A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions de modificateur de réponse biologique synthétique. Cette composition de modificateur de réponse biologique synthétique (Syn-BRM) contient: 57 ? 20 mg/l d'acide de 3-hydroxybutyrique, 22 ? 8 mg/l de créatinine, 2,5 ? 0,9 mg/l de carnitine, 6,8 ? 2,4 mg/l de taurine, 20 ? 7 mg/l de choline, 815 ? 285 mg/l d'urée. Ces compositions peuvent, en outre, comprendre 40 ? 14 mg/l d'acide formique. Les compositions de modificateur de réponse biologique synthétique modifient la réponse biologique <i>in vivo</i>, présentant une activité anticancéreuse et améliorent la réponse immunitaire induite par des cellules à des tumeurs. Cette invention concerne également des combinaisons anticancéreuses comprenant une composition de modificateur de réponse biologique synthétique et un ou plusieurs agents anticancéreux, cette combinaison améliorant le traitement des cancers par rapport à la composition ou aux agents anticancéreux utilisés seuls. Un autre aspect de l'invention concerne l'utilisation de compositions de modificateur de réponse biologique synthétique ou d'une combinaison anticancéreuse correspondante dans la fabrication d'un médicament ou d'un nécessaire pharmaceutique et dans le traitement du cancer.
CA002451674A 2001-06-20 2002-06-20 Composition d'un modificateur de reponse biologique et utilisations de celle-ci Abandoned CA2451674A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002451674A CA2451674A1 (fr) 2001-06-20 2002-06-20 Composition d'un modificateur de reponse biologique et utilisations de celle-ci

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CA2,351,169 2001-06-20
CA2351169 2001-06-20
CA2,380,967 2002-04-08
CA2380967 2002-04-08
CA002451674A CA2451674A1 (fr) 2001-06-20 2002-06-20 Composition d'un modificateur de reponse biologique et utilisations de celle-ci
PCT/CA2002/000932 WO2002102363A1 (fr) 2001-06-20 2002-06-20 Composition d'un modificateur de reponse biologique et utilisations de celle-ci

Publications (1)

Publication Number Publication Date
CA2451674A1 true CA2451674A1 (fr) 2002-12-27

Family

ID=31949997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451674A Abandoned CA2451674A1 (fr) 2001-06-20 2002-06-20 Composition d'un modificateur de reponse biologique et utilisations de celle-ci

Country Status (1)

Country Link
CA (1) CA2451674A1 (fr)

Similar Documents

Publication Publication Date Title
US8394418B2 (en) Combination preparation of a biological response modifier and an anticancer agent and uses thereof
Enria et al. Antiviral treatment of Argentine hemorrhagic fever
Kalechman et al. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention
EP1809738B1 (fr) Compositions et procedes pour traiter des etats hyperproliferatifs
WO2011097480A1 (fr) Compositions exosomales et procédés pour le traitement de maladies
US20040198819A1 (en) Biological response modifier composition and uses thereof
CA2451674A1 (fr) Composition d&#39;un modificateur de reponse biologique et utilisations de celle-ci
Zhang et al. Anti‐PD‐1 Antibody administration following hip fracture surgery reverses immune dysfunction and decreases susceptibility to infection
WO2015194643A1 (fr) Inhibiteur de la croissance cellulaire dépendant de pdgf, procédé d&#39;inhibition de la croissance cellulaire dépendant de pdgf, inhibiteur de la dispersion des cellules, procédé d&#39;inhibition de la dispersion des cellules, renforçateur de l&#39;activité du témozolomide, et agent antitumoral
CN108042807B (zh) 作为辐射缓和剂和辐射防护剂的bpi和其同源物的用途
KR100835877B1 (ko) 천연 킬러 세포의 증식제 및 증식 방법
WO2017159835A1 (fr) Agent thérapeutique pour un néoplasme de plasmocytes
CN112823808B (zh) 用于制备治疗上皮细胞癌的医药组合物及其用途
US20100322895A1 (en) T cell depleting compositions useful for treating cancer
US20050192443A1 (en) Biological response modifier for the treatment of cancer
US20150329824A1 (en) Z cells activated by zinc finger-like protein and uses thereof in cancer treatment
US8338383B1 (en) Use of immunomodulators for the treatment of cancer
KR101622787B1 (ko) 패혈증에 의한 염증성 질환의 예방 및 치료용 약학적 조성물
US8236354B1 (en) Use of immunomodulators for the treatment of cancer
CA2428145A1 (fr) Preparation combinee d&#39;un modificateur de reponse biologique et d&#39;un agent anticancereux et utilisations de cette derniere
Yan et al. Anti-IL-10 Therapeutic Strategy Using the
NZ576636A (en) A method for screening for a substance having an action of proliferating natural killer cells
Baigrie Cytokine and other components of the integrated host response to injury
Ganbold Hepatic Steatosis, Ischaemia/Reperfusion injury and Survival Cytokines in Spontaneous Liver Transplant Tolerance
US20070243164A1 (en) Treating Skin Cancer

Legal Events

Date Code Title Description
FZDE Dead